Antibody-drug conjugates (ADCs) are potent cytotoxic drugs linked to antibodies through chemical linkers, and allow specific targeting of drugs to neoplastic cells. The expression of CD22 is limited to B-cells, and we show that CD22 is expressed on the vast majority of non-Hodgkin's lymphomas (NHLs). An ideal target for an ADC for the treatment of NHL would have limited expression outside the B-cell compartment and be highly effective against NHL. We generated an ADC consisting of a humanized anti-CD22 antibody conjugated to the anti-mitotic agent maytansine with a stable linker (anti-CD22-MCC-DM1). Anti-CD22-MCC-DM1 was broadly effective in in vitro killing assays on NHL B-cell lines. We did not find a strong correlation between in vitro potency and CD22 surface expression, internalization of ADC or sensitivity to free drug. We show that anti-CD22-MCC-DM1 was capable of inducing complete tumor regression in NHL xenograft mouse models. Further, anti-CD22-MCC-DM1 was well tolerated in cynomolgus monkeys and substantially decreased circulating B-cells as well as follicle size and germinal center formation in lymphoid organs. These results suggest that anti-CD22-MCC-DM1 has an efficacy, safety and pharmacodynamic profile that support its use as a treatment for NHL.
Introduction
B-cell non-Hodgkin's lymphomas (NHLs) are diverse neoplasms that vary widely in clinical outcome. 1 Standard treatment for most subtypes of NHL usually involves combination chemotherapy and/or rituximab (anti-CD20 monoclonal antibody therapy), and in some cases such therapies can be curative. However, most NHLs are not cured and result in 19 660 mortalities per year in the United States, 2 underscoring the need for more effective therapies to improve patient outcome.
One approach for the treatment of NHL that has potential for increased efficacy is the use of antibody-drug conjugates (ADCs); these are cytotoxic drugs covalently linked to antibodies through specialized chemical linkers. ADCs provide a means to improve the potency of chemotherapy by increasing the accumulation of cytotoxic drug within neoplastic cells, while reducing the non-specific systemic effects of cytotoxic drug administration. 3, 4 To accomplish this specificity, specialized linkers between the antibody and drug have been designed. These linkers are of two types; one is cleaved only in a specific microenvironment found in or on the target tumor cell. Examples include linkers that are cleaved by acidic conditions, reducing conditions or proteases. [5] [6] [7] A second type of linker is stable; it is not readily cleaved, but is instead coupled to antibodies against tumor antigens that are internalized and then degraded, thus releasing the drug still attached to the conjugating amino acids. 8, 9 Preclinical data suggest that these linker-drugs are more stable in circulation, which provides the possibility of dosing at higher levels without encountering the toxicity from the free drug or its metabolites. 10 The stable linker ADC approach is showing promise in the clinic. Trastuzumab-DM1 (an anti-Her2 antibody conjugated on lysine residues to an anti-mitotic tubulin inhibitor, maytansinoid N(2 0 )-deacetyl-N(2 0 )-(3-mercapto-1-oxopropyl)-maytansine (DM1), through the uncleavable thioether linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (MCC)) is showing encouraging efficacy and safety in the treatment of Her2 þ breast cancer. 11, 12 While the stable linker ADCs provide the potential to have lower toxicity and thereby allowing dosing to higher levels, they are also effective on fewer targets than linkers that are designed to be cleaved by conditions in or near the tumor cells. 10 Our previous study has shown that stable linker ADCs that recognize CD22 can be used effectively to target neoplastic cells. 10 Here we describe the generation, identification and humanization of an anti-CD22 antibody for use as an ADC and present efficacy and safety data for anti-CD22-MCC-DM1 that suggest this conjugate could be used in humans for the treatment of NHL.
Materials and methods

Antibodies and ADC
A panel of anti-CD22 antibodies (both mouse and human) were made in mice as previously described. 13 In these experiments, purified His-8 tagged human CD22 extracellular domain that was either full-length or lacking domains 3 and 4 was used as the immunogen. Anti-CD22 (10F4) was selected and humanized at Genentech (South San Francisco, CA, USA) using previously described methods.
14 Conjugation of hu10F4 with MCC-DM1 was performed as previously described. 15 
Xenograft models
All animal studies were performed in compliance with National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the Institutional Animal Care and Use Committee (IACUC) at Genentech. Cells for implantation were washed and suspended in Hank's balanced salt solution (Hyclone, Frolunda, Sweden) and inoculated subcutaneously into the flanks of female CB17 ICR severe combined immunodeficiency mice (7-16 weeks of age from Charles River Laboratories; Hollister, CA, USA), in a volume of 0.2 ml/mouse. When mean tumor size reached the desired volume, the mice were divided into groups of 8-10 mice with the same mean tumor size, and dosed intravenously through the tail vein with ADCs or antibodies. In some cases, the doses of ADCs given to the mice were measured as the mass of the conjugated cytotoxic small molecule drugFfor example, dosing with 300 mg antibody-linked DM1/m 2 (surface area of the mouse). In other cases, the mice were dosed with a constant mass of ADCFfor example, 5 mg of ADC per kg (weight of the mouse). Within each experiment the dosing method was constant. In general, the drug loads on the antibodies in a given experiment were similar (3-4 drug molecules per antibody), so these two measures can be considered equivalent.
In vitro efficacy, CD22 surface expression and ADC internalization studies
To measure cell killing, cell lines were cultured in complete RPMI (RPMI-1640, 10% fetal calf serum, 100 i.u/ml penicillin, 100 mg/ml streptomycin and 2 mM for L-glutamine), harvested in log phase growth, and 5000 cells per well were seeded into a 96-well plate in 90 ml medium per well. Triplicate assays for ADC or free drug were done by adding 3-fold serial dilutions starting from 300 mg/ml (ADC) or 90 nM (free drug), and incubating at 37 1C for 3 days. Cell killing was measured using CellTiter Glo (Promega, Madison, WI, USA) as described by the manufacturer, and the data analyzed using Prism software (Prism Software, Irvine, CA, USA).
To measure antigen-surface expression, cells were resuspended in FACS wash (phosphate-buffered saline; 0.5% bovine serum albumin; 0.1% sodium azide) containing 100 mg/ml (each) normal mouse immunoglobulin (Ig)G and normal human IgG, and incubated on ice. Approximately 0.5-1.0 Â 10 6 cells/100 ml were stained with anti-huCD22-APC (mIgG 1 ; RFB4; Southern Biotech, Birmingham, AL, USA) or mIgG 1 APC isotype (BD Pharmingen, San Diego, CA, USA) for 30 min on ice. Dead cells were detected with 7-AAD (BD Pharmingen). Flow cytometry data were acquired on a BD FacsCalibur flow cytometer and analyzed with FlowJo software (Tree Star Inc., Ashland, OR, USA). Mean fluorescence intensities (MFIs) were calculated using FlowJo software; the reported MFI is that of the anti-CD22 minus the MFI of the isotype control.
To measure the amount of internalized ADC, 4 Â 10 6 cells were first incubated in 400 ml staining buffer (phosphatebuffered saline, 2% fetal bovine serum, 2 mM ethylene di-amine tetra acetic acid) in the presence of 20% normal human serum type AB with anti-CD22 (hu10F4)-MCC-DM1 (1 mg/100 ml) on ice (no or minimal internalization) for 15 min. The cells were then washed twice in cold FACS wash and split into two 200 ml fractions; one fraction (used for total surface-bound ADC measurement) was incubated in 100 ml of staining buffer in the presence of 20% mouse serum for 15 min on ice, followed by staining with 1 mg/100 ml of anti-DM1-Alexa-647 for 30 min on ice. The second fraction (used for ADC internalization) was resuspended in complete RPMI and incubated at 37 1C for 30 min. The cells were then washed twice with cold FACS wash and incubated with 100 ml of staining buffer in the presence of 20% mouse serum on ice for 15 min, followed by staining with 1 mg/100 ml of anti-DM1-Alexa-647 for 30 min on ice. Each fraction was then washed twice with cold FACS wash and fixed with phosphate-buffered saline/1% paraformaldehyde. Cells were acquired on a BD FACSCalibur flow cytometer and analyzed with FlowJo software. The amount of internalized ADC was calculated as the anti-DM1-Alexa-647 MFI of the cells on ice (total surface ADC) minus the MFI of the cells after incubation at 37 1C (residual surface).
Surface CD22 expression on primary NHL samples
The CD22 expression in patient samples was determined using the S-HCL-1 clone (BD Biosciences, UK). Whole blood (50 ml) was distributed into a 96-well microtiter plate, and RBCs were lysed using ammonium chloride (8.6 g/l, Vickers Laboratories, UK). The cells were washed twice with FACSFlow (Becton Dickinson, Franklin Lakes, NJ, USA)/0.1% bovine serum albumin solution (Sigma, St Louis, MO, USA). The pellets were resuspended with 20 ml of individual antibody cocktails to assess the phenotype of the B-cell tumors. The cells were mixed on a plate shaker and incubated at 4 1C for 20 min. FACSFlow/0.1% bovine serum albumin was added to the plates and the cells were washed by centrifugation at 2000 r.p.m. for 5 min. This washing step was repeated and the cells were resupended in FACS Flow buffer. All samples were acquired on a FACSort instrument and analyzed with CellQuest. All tumor cells were gated using forward/side scatter properties as well as the B-cell marker CD19 (Caltag, UK, Clone SJ25-C1). Anti-CD3 PE (BD Biosciences, UK, Clone SK7) was used to determine nonspecific staining staining within the CD19 positive gate and served as an isotype control for anti-CD22 PE. All geometric mean fluorescense intensity values for CD22 were normalized by subtraction of the CD3-PE fluorescence values. The data are shown as LOG2 geometric mean fluorescence intensity.
Cynomolgus monkey safety study
A cynomolgus monkey (Macaca fascicularis) safety study was conducted at Charles River Laboratories (CRL, Sparks, NV, USA) according to their standard operational procedures and in compliance with National Institutes of Health regulations concerning the use of laboratory animals. Eighteen Indonesian female cynomolgus monkeys (2-6 years old; 2-5 kg) were assigned to four dose groups (six animals in the vehicle control group and four animals per test article group) using a stratified randomization scheme, which was based on individual animal body weights and CD20 þ absolute lymphocyte counts. Animals were dosed intravenously on day 1 and day 22 with vehicle or anti-CD22 (hu10F4)-MCC-DM1 at 2000, 4000 or 6000 mg antibody-linked DM1/m 2 (B10, 20 and 30 mg/kg ADC, respectively), and were monitored daily for mortality, clinical abnormalities and food consumption. Body weights were measured twice during the pre-dose phase, weekly throughout the study, and on the day of necropsy. Analyses of hematology, clinical chemistry, coagulation, toxicokinetics (total anti-CD22 (hu10F4), anti-CD22 (hu10F4)-MCC-DM1 and free DM1) and anti-therapeutic antibody were performed on blood collected during the pre-dose phase and at various time points throughout the study. Total anti-CD22 (hu10F4), anti-CD22 (hu10F4)-MCC-DM1 and free DM1 were analyzed as previously described. 16 All animals were euthanized and necropsied on either day 25 or 43 and tissues were thoroughly evaluated by gross and microscopic examination. Urinalysis was performed on urine collected by cystocentesis at necropsy.
Flow cytometry of peripheral blood and tissue
Flow cytometric analysis of peripheral blood B-cells
and NK cells (CD3ÀCD20À) was performed at Shin Nippon Biomedical Laboratories (SNBL, Everett, WA, USA). The following combinations were used: IgG-FITC, IgG-PE and IgG-APC (tube 1, isotype controls); anti-CD3-FITC, anti-CD4-PE and anti-CD8-APC (tube 2); anti-CD3-FITC, anti-CD16-PE and anti-CD20-APC (tube 3); anti-CD27-FITC, anti-CD21-PE and anti-CD20-APC (tube 4) (BD Pharmingen). Whole blood (0.1 ml) was added to the immunophenotyping antibody cocktail and incubated in the dark at ambient room temperature for approximately 15-20 min. Leukocytes were isolated by whole blood lysis using BD Pharm Lyse Solution (Becton Dickinson) according to the manufacturer's instructions. Cells were washed once by adding 2 ml of calcium-free and magnesium-free phosphate-buffered saline, resuspended in 300 ml of 0.5% formaldehyde in calcium-free and magnesium-free phosphatebuffered saline, and analyzed by flow cytometry. Relative percentages and absolute counts were tabulated for each lymphocyte subset and further analyzed as a percentage of the pre-dose baseline for each individual animal. Absolute counts were calculated from relative percentages and the absolute lymphocyte counts (from the hematology samples) according to the formula: absolute count ( Â 10 3 /ml) ¼ (relative percentage Â lymphocyte absolute count ( Â 10 3 /ml)/100). The pre-dose baseline was defined as the average of values collected before the first dose (day 14, day À7 and day 1 pre-dose).
Tissues (spleen, mesenteric and mandibular lymph nodes) and bone marrow were processed into single cell suspensions and passed through a 100 mm nylon screen cell strainer. Samples were then washed twice with phosphate-buffered saline/0.5% bovine serum albumin and counted on a Z2 Coulter Counter (Millipore, Billerica, MA, USA). The cell number was adjusted to 30 Â 10 6 per ml and immunostained as per whole blood tubes 1 and 4. In all 200 000 lymphocyte gated events were collected for tube 4. Flow cytometric analysis of tissue B-cells (CD20 þ ) and B-cell subsets
Immunohistochemistry
Adjacent sections of spleen from each animal were collected, with one section fixed in 10% neutral buffered formalin and embedded in paraffin, and the other placed into a cryomold surrounded by Tissue-Tek Optimal Cutting Temperature (OCT) compound (Sakura Finetek, Torrance, CA, USA) and flashfrozen in dry ice and 2-methylbutane, for immunohistochemistry evaluation. Formalin-fixed tissues were sectioned at 5 mm on glass slides, deparaffinized and hydrated to distilled water. Slides were incubated for 20 min in target retrieval solution (Dako, Glostrup, Denmark) at 99 1C. Endogenous peroxidases were quenched using a blocking solution (KPL, Gaithersberg, MD, USA, 71-00-10) and endogenous biotin was blocked using an avidin/biotin blocking kit (Vector Laboratories, SP-2001). Slides were incubated with 1 mg/ml anti-Ki-67 (clone MIB-1 from Dako, M7240) followed by an incubation with 2.5 mg/ml biotinylated horse anti-mouse IgG (H þ L) (Vector Laboratories, BA-2001). Frozen tissues were sectioned at 5 mm, air dried on glass slides and fixed in acetone. Endogenous peroxidases were quenched as described above. Slides were incubated with 1 mg/ml anti-IgD (Dako, A0093) followed by an incubation with 2 mg/ml biotinylated donkey anti-rabbit secondary antibody (Jackson Immunoresearch, West Grove, PA, USA, 711-056-152). All slides were incubated with Vectastain ABC Elite Reagents (Vector Laboratories, Burlingame, CA, USA) and Pierce Metal Enhanced DAB (Thermo Fisher Scientific, Waltham, MA, USA). Slides were counterstained with Mayer's hematoxylin for viewing by light microscopy.
Results
Anti-CD22-MCC-DM1 is broadly effective in vitro against multiple NHL cell lines
To develop the optimal anti-CD22 antibody for use in the clinic we assessed the in vivo efficacy of various MCC-DM1 conjugated anti-CD22 ADCs. We assayed for the vivo efficacy of the ADCs to select an antibody because the antibody determinants of ADC clinical efficacy are largely unknown. Therefore, we chose the most relevant assay we could (in vivo efficacy). The antibodies had varying efficacy, which did not relate to epitope, affinity or isotype (Supplementary Figure 1) . Additionally, to enable target-dependent toxicity studies, the ability of the antibodies to bind to B-cells from cynomolgus monkeys was examined by flow cytometry (data not shown). Using these two criteria, the antibody 10F4 was selected as the one with the highest potential, and 10F4 was humanized on an IgG1 scaffold.
14 The resulting conjugate, anti-CD22(hu10F4; huIgG1)-MCC-DM1, is referred to here as anti-CD22-MCC-DM1.
As NHL is clinically heterogeneous, varying widely in genetic drivers of transformation, the effect of anti-CD22-MCC-DM1 on an array of NHL lines was examined. The in vitro efficacy was assessed on 18 different B-cell lines (Supplementary Table 1,  Supplementary Table 2 ). All but one of the cell lines were more sensitive to the cytotoxic effect of anti-CD22-MCC-DM1 than control Jurkat cells (IC 50 ¼ 12 000 ng/ml), which do not express CD22 but are sensitive to free DM1 (IC 50 ¼ 0.5 nM) (data not shown). Rec-1 cells, which are unusually resistant to free DM1, were similar to control Jurkat cells in sensitivity. Trastuzumab-MCC-DM1 was used as a control and no substantial internalization was seen with any of the cell lines tested (data not shown). These data indicate that anti-CD22-MCC-DM1 could be broadly efficacious against CD22-expressing malignancies, while not affecting non-targeted cells.
Interestingly, the amount of expression of CD22 and the amount of internalized ADC showed modest correlations to the sensitivity of a given cell line to the ADC (R 2 ¼ 0.23 and 0.37, respectively Figure 1 panel 2 and 3 ). However, there was a stronger correlation between the sensitivity of a given cell line to free drug and the sensitivity to the ADC (R 2 ¼ 0.66) (Figure 1  panel 1) . A number of factors can impact the sensitivity of a cell line to the ADC: target copy number, rate of internalization, metabolism of the ADC to release the active drug, sensitivity of the cell line to the drug and in vivo ADC access to the tumor and the tumor microenvironment. Thus, it is not surprising that not just one factor will completely predict the sensitivity of a given cell line to an ADC.
We also compared the in vitro efficacy of anti-CD22-MCC-DM1 with anti-CD79b-MCC-DM1, another ADC with the same linker drug but a different target. 15, 17 We found no correlation between the potency of these two ADCs, although the CD79b ADC had a greater average potency (Supplementary Table 2 , Supplementary Figure 2) .
The lack of activity of the Trastuzumab-MCC-DM1 on CD22-expressing cell lines (data not shown) and the lack of anti-CD22-MCC-DM1 activity on the CD22-negative cells suggest that CD22 expression is necessary for the efficacy of anti-CD22 ADC. However, high CD22 levels are not required, as some of the cell lines with very low expression of CD22 were sensitive to killing by anti-CD22-MCC-DM1 (example, Pfeiffer and Oci-ly-19, Supplementary Table 2 ).
Given that some expression of CD22 is required to elicit activity, the prevalence of expression of CD22 on the cell surface of primary human lymphoma and chronic lymphocytic leukemia samples was assessed to estimate a patient population that may benefit from an anti-CD22-ADC. CD22 expression was detectable in all cases of chronic lymphocytic leukemia, marginal zone lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma (Figure 2a ). Similar levels of CD22 expression were expressed on diffuse large B-cell lymphoma, follicular lymphoma and marginal zone lymphoma tumor cells. Hairy cell leukemia patients showed slightly increased CD22 expression levels as compared with other tumor types, as well as normal B-lymphocytes (Figure 2a) . Furthermore, in all cases of follicular lymphoma and diffuse large B-cell lymphoma, levels of CD22 in patients who had relapsed from prior treatments were similar to levels measured at diagnosis, highlighting the clinical relevance of the target and potential therapeutic use of anti-CD22-MCC-DM1 (Figure 2b ). These data suggest that most patients with chronic lymphocytic leukemia and NHL are potential candidates for the treatment by anti-CD22-MCC-DM1.
Administration of anti-CD22-MCC-DM1 can provide sustained tumor regression in vivo
To assess the potential of anti-CD22-MCC-DM1 in vivo, the efficacy of the anti-CD22-MCC-DM1 was assessed in xenograft models of NHL, using three different NHL lines: Burkitt's lymphoma, Granta-519 (mantle cell lymphoma) and DoHH2 (follicular lymphoma). Control MCC-DM1 conjugates that did not bind these tumor cells (Trastuzumab-MCC-DM1) and unconjugated anti-CD22 had no effect on tumor growth in the models (Figure 3 , data not shown) 10 . In contrast, the Burkitt's lymphoma and Granta-519 xenograft tumors were completely ablated by anti-CD22-MCC-DM1 administered at 3-weekly doses of 600 mg antibody-linked DM1/m 2 (B12 mg ADC/kg) ( Figure 3) . The DoHH2 follicular lymphoma cell line was the most resistant line, displaying only slightly delayed tumor growth. These studies show that anti-CD22-MCC-DM1 has potential as a highly effective therapy in the treatment of NHL.
Anti-CD22-MCC-DM1 decreased peripheral blood and tissue B-cells and was well tolerated in cynomolgus monkeys
To confirm cynomolgus monkeys as a binding species, anti-CD22 binding to Chinese hamster ovary cells recombinantly expressing human or cynomolgus monkey antigen, was quantitated by Scatchard analysis. The kd for anti-CD22 hu10F4 MAb was similar for cynomolgus monkey and human recombinantly expressed CD22 (2.1 ± 0.2 nM and 1.6 ± 0.2 nM, respectively, as measured by equilibrium binding assay, data not shown). These data indicate that cynomolgus monkeys are an The pharmacodynamic effects of anti-CD22-MCC-DM1 on the targeted normal B-cells in peripheral blood and tissue were assessed by flow cytometry and immunohistochemistry (Figure 4) . B-cell depletion in peripheral blood was observed at all dose levels, reaching a maximum group mean depletion of 480% of pre-dose levels (Figure 4a ). In contrast, T and NK cells showed minimal changes in blood compared with animals dosed with vehicle ( Figure 4b ). To determine effects on circulating B-cell subsets, CD20 þ CD21À, CD20 þ CD21 þ CD27À and CD20 þ CD21 þ CD27 þ B-cells (phenotypically similar to human germinal center, naïve and memory B-cells, respectively) were also assessed (Supplementary Figure 3) . CD20 þ CD21À B-cells are not observed in circulation of healthy humans; however, this particular subset is observed in peripheral blood of cynomolgus monkeys. Substantial depletion was observed in all three B-cell subsets at each dose level, with a trend in depletion at earlier time points in the CD20 þ CD21-B-cell subset.
At necropsy, B-cell levels were also assessed in lymphoid tissues by flow cytometry (bone marrow, lymph nodes and spleen), histology (tonsil, lymph nodes and spleen) and immunohistochemistry (spleen). Lymphoid tissue B-cells were depleted in the majority of the animals at all dose levels (data not shown). Decreased follicle size and absence of germinal center formation (depletion of Ki-67 þ dividing cells) was observed in spleen, tonsil and lymph nodes on days 25 and 43 at all doses (Figure 4c) . These results agree with the expected mechanism of action and suggest that anti-CD22-MCC-DM1 has the potential to provide similar targeting of proliferating cells in NHL.
Dose-related, minimal to mild decreases in lymphocyte and platelet counts were observed in animals given anti-CD22-MCC-DM1 at 4000 and 6000 mg/m 2 ( Figure 5 ). At 6000 mg/m 2 , anti-CD22-MCC-DM1 also caused minimal to mild elevations in alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase, globulin and mild decreases in albumin and albumin/globulin ratio (A/G ratio) suggestive of an effect on the liver ( Figure 5 ; data not shown). Microscopic evaluation revealed minimal changes in the nuclear morphology of liver Kupffer cells in all ADC dose groups (nuclear chromosomal condensation, presumed mitotic arrest) and depletion of thymic lymphocytes in the 4000 and 6000 mg/m 2 groups. As CD22 is not expressed on platelets, hepatocytes or Kupffer cells, these changes were considered to be because of the anti-mitotic effect of the systemic release of conjugate drug or the non-specific uptake of the ADC, and not target-specific. Minimal to mild axonal degeneration of the sciatic nerve was observed in all anti-CD22-MCC-DM1 dose groups, a finding not unexpected with a molecule that inhibits tubulin polymerization.
The pharmacokinetic profiles of the conjugate and the total antibody showed typical biphasic disposition with a rapid distribution phase followed by a slower elimination phase (Supplementary Figure 4) . The conjugate cleared about two-fold faster than the total antibody (Supplementary Figure 4) . At the highest dose of 30 mg/kg, peak plasma concentrations of the conjugate were B700 mg/ml. The elimination half-life of the conjugate was 6-7 days. Free DM1 concentrations showed multiphasic disposition in the plasma and were roughly 10 000-fold lower than conjugated antibody in mass unit (data not shown). The amount of free DM1 increased slightly with increasing dose (data not shown).
From this study, we concluded that anti-CD22-MCC-DM1 was well tolerated in cynomolgus monkeys at doses up to 6000 mg antibody-linked DM1/m 2 (B30 mg/kg) and no toxicities were observed that would preclude its use in the treatment of NHL.
Discussion
Antibody-drug conjugates offer the promise of increasing both the efficacy and safety of chemotherapeutic regimens by directing drugs specifically to tumor targets, and increasing the therapeutic window of drugs that are too potent to be used systemically. Here we describe the generation and therapeutic potential of the ADC, anti-CD22-MCC-DM1. Anti-CD22-MCC-DM1 is effective against most B-cell lines in vitro and in vivo. In two of the three xenograft tumor models tested, the treatment with anti-CD22-MCC-DM1 resulted in complete tumor regression. Our data also suggest that low CD22 expression should not pose a limitation to the number of patients that may respond to anti-CD22-MCC-DM1. Some cell lines with very low expression of CD22 were sensitive to killing by anti-CD22-MCC-DM1 (example, Pfeiffer and Oci-ly-19, Figure 1 ) and the majority of the NHL patients express CD22. Furthermore, even NHL patients that have relapsed from prior treatments continue to express CD22. Another encouraging observation for the efficacy of these ADCs is the preferential depletion of germinal center B-cells in cynomolgus monkeys dosed with anti-CD22-MCC-DM1 (Figure 4 ) as this population resembles NHL in its rapid division and tissue microenvironment. While the depletion of germinal center B-cells is the expected anti-mitotic pharmacological effect and encouraging, equating depletion of B-cells in general as a sign of efficacy should be treated with some caution. We do not see any efficacy in the xenograft models with unconjugated anti-CD22 and it is possible that some of the B-cell depletion we observed comes from effector function as peripheral B-cell depletion has been previously observed with unconjugated anti-CD22 antibodies evaluated in humans. 18 This could mean that the mechanisms of B-cell depletion and tumor efficacy may be slightly different, at least for circulating cells. The depletion of B-cells is not considered a major safety concern, as rituximab (anti-CD20) results in extensive depletion of B-cells without causing marked immunocompromise or other immune tolerance issues.
The work presented here suggests that anti-CD22-MCC-DM1 is a promising potential therapeutic for the treatment of NHL. We found that anti-CD22-MCC-DM1 was safe at 30 mg/kg (q3wks Â 2 cycles over 6 weeks); the total exposure (area under the plasma concentration time curve) at this dose and dosing regimen, 2810 mg/ml Â day, was slightly more than the total exposure in mice that were administered 12 mg/kg q3wks Â 3 (AUC B2529 mg/ml Â day) as shown in Figure 3a where we observed sustained durable remission of all the tumors over 6 weeks.
These data show that anti-CD22-MCC-DM1 has potent efficacy in xenograft models of NHL, an acceptable safety profile in a pilot animal safety study in nonhuman primates and suggest that for specific targets, uncleavable linkers provide a promising mechanism to improve both efficacy and safety in humans.
There are several ADCs for the treatment of B-cell lymphoma in early clinical trials using different linker drugs than the MCC-DM1 linker described here; CMC-544, which is an anti-CD22 attached to calicheamycin by an acid cleavable linker [19] [20] [21] and SAR3419, an anti-CD19 antibody attached to the maytansinoid DM4 by a reducible linker. Both of these conjugates are showing efficacy in the early clinical trials. 22, 23 We have also described two anti-CD79b conjugates for the treatment of lymphoma. 10, 15, 17, 24 Given that all of these ADCs have different linker-drugs it is likely that they have different safety and efficacy profiles. One of the previously described ADCs for the treatment of NHL, anti-CD79b ADC, is also an MCC-DM1 conjugate. 15, 17 Our data suggest that anti-CD22-MCC-DM1 and anti-CD79b-MCC-DM1 have different drivers of efficacy as reflected by the observation that there is no correlation in their in vitro efficacy (Supplementary Figure 2) and that those drivers of efficacy are not the obvious candidates (target levels, internalization and sensitivity to free drug), suggesting that the complex interaction of the biology of the targets with the ADCs will lead to very different clinical properties, even if the targets have similar expression patterns and the linker-drugs used in the ADCs are identical. This diversity and the promising clinical and pre-clinical data for ADCs in the treatment of NHL suggest that antibody drug conjugates have the potential to become effective and useful treatments for B-cell malignancies. Fiona Zhong, Bing Zheng and Kristi Elkins for technical support, Figure 5 Effect of anti-CD22-MCC-DM1 on clinical pathology in cynomolgus monkeys. Cynomolgus monkeys were given two intravenous doses of anti-CD22-MCC-DM1 at 2000, 4000 or 6000 mg antibody-linked DM1/m 2 (B10, 20 and 30 mg/kg ADC) or vehicle, 3 weeks apart (n ¼ 4 animals/group, except for the control group where n ¼ 6). Two animals per group were euthanized and evaluated on days 25 or 43 of the study, with the exception of three animals on each day in the control group. Clinical pathology parameters are shown for four animals up to day 25, and two animals thereafter. ALP; alkaline phosphatase, AST ;aspartate aminotransferase. Mild decreases in red blood cell mass (red blood cell counts, hemoglobin and hematocrit) were seen in all groups because of blood collection, but were more evident in ADC-dosed groups (data not shown).
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